Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Times of New York.
Press releases published on July 30, 2025

Dragonfly Energy Announces Pricing of $5.5 Million Public Offering of Common Stock
RENO, Nev., July 30, 2025 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI), an industry leader in energy storage and battery technology, today announced the pricing of an underwritten public offering …

Acorn, Provider of Remote Monitoring and Control Solutions for Backup Power Generators, Hosts Q2 Earnings Call on Thur. August 7th at 11am ET
WILMINGTON, Del., July 30, 2025 (GLOBE NEWSWIRE) -- Acorn Energy, Inc. (Nasdaq: ACFN), a provider of remote monitoring and control solutions for backup power generators, gas pipelines and other industrial equipment, will report its second quarter results …

Enlight Expands Its Executive Leadership Team
Gilad Yavetz, founder of Enlight, to serve as Executive chairman of the board Adi Leviatan to be appointed CEO, bringing a proven track record of executive leadership from leading global companies; Yair Seroussi to serve as vice chairman This step, …

PMGC Holdings Inc. Terminates LOI to Focus on Acquiring High-Growth CNC Precision Manufacturing Companies Serving Aerospace, Defense, and Industrial Markets
NEWPORT BEACH, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (the “Company”, “PMGC” or ”we”), a diversified public holding company, today announced that it has terminated the previously announced non-binding letter of intent, …

BriaCell Awarded New Zealand Patent for its Whole Cell Technology
PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to …

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data …

Creative Realities, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call Information
LOUISVILLE, K.Y., July 30, 2025 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX), a leading provider of digital signage and media solutions, announced today that it will release its financial …

First National Corporation Reports Record Second Quarter 2025 Earnings
STRASBURG, Va., July 30, 2025 (GLOBE NEWSWIRE) -- First National Corporation (the “Company” or “First National”) (NASDAQ: FXNC), the bank holding company of First Bank (the “Bank”), reported earnings for the quarter ended June 30, 2025 of $5.05 million and …

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products
DURHAM, N.C., July 30, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, announced today a significant milestone with the U.S. Food and Drug Administration (FDA) 510(k) clearances for both TalisMann™ …

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update
NEW YORK, July 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 4, 2025, at 8:30 AM ET to discuss results for the second quarter of 2025 and provide a business outlook …

NextGen Digital Platforms Announces Plans to Expand AI Strategy through Integration with Bittensor Network
Vancouver, BC, July 30, 2025 (GLOBE NEWSWIRE) -- NextGen Digital Platforms Inc. (CSE:NXT) (OTCQB:NXTDF) (FSE:Z12) (“NextGen” or the “Company”) is pleased to announce its planned strategic integration with the Bittensor (TAO) ecosystem, a decentralized …

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) …

Humanoid Global Appoints Dr. Yue Hu to Humanoid Technical Advisory Committee
Vancouver, BC, July 30, 2025 (GLOBE NEWSWIRE) -- Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCPK:RBOHF), a publicly traded investment issuer focused on the humanoid robotics and embodied AI sector, is pleased …

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA Presented additional analyses from the ATH434-201 trial …

Fortune 50 Telecommunication Company Purchases Multiple Draganfly Heavy Lift Drone Systems for Emergency Response and Disaster Recovery Infrastructure Support
Tampa Bay, Florida, July 30, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning developer of drone solutions and systems, and Infinity Communications, a premier provider of rapid …

Verisk Reports Second-Quarter 2025 Financial Results
Second quarter revenue of $773 million, up 7.8%, and up 7.9% on an organic constant currency (OCC) basis. Net income of $253 million, down 17.7% due to gains recognized in the prior year. Adjusted EBITDA, a non-GAAP measure, of $445 million, up 11.9%, and …

Anika Reports Second Quarter 2025 Financial Results
Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results …

Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a …

Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements …

Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress
LONDON and PHILADELPHIA, July 30, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, ‘the Company’), a life sciences company developing innovative, targeted oncology drugs, today announces that the Company will present an updated data analysis from …